Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based 'Newco,' explain experts at Orrick.

By Stephen Beckman Stephen Beckman A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

By Ben Comer, Chief Editor, Life Science Leader Adam Mendelsohn, Ph.D. Overcoming adherence and tolerability issues in obesity and diabetes treatment. Snapshot Vivani’s subdermal implant NanoPortal ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

For more than two decades, the EU has pledged numerous initiatives aimed at creating regulatory environments to foster both innovation and investment in the EU’s biotech sector, a sector which broadly ...

By Carolina Ahrendt Carolina Ahrendt What does strategy look like for a drug development program? The word strategy can mean different things to different individuals. If you polled a group on a ...